Abstract LB-206: The role of fibroblast activation protein (FAP) in lung tumorigenesis

Author(s):  
Diana Avery ◽  
Michelle Jacob ◽  
Lisa Chang ◽  
Leslie Todd ◽  
Ellen Pure
2018 ◽  
Vol 83 (4) ◽  
pp. 381-387 ◽  
Author(s):  
Ana Carolinne da Silva ◽  
Millena Prata Jammal ◽  
Renata Margarida Etchebehere ◽  
Eddie Fernando Candido Murta ◽  
Rosekeila Simões Nomelini

PET Clinics ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. 341-351
Author(s):  
Katharina Dendl ◽  
Joel Schlittenhardt ◽  
Fabian Staudinger ◽  
Clemens Kratochwil ◽  
Anette Altmann ◽  
...  

2019 ◽  
Vol 20 (1) ◽  
pp. 121-130
Author(s):  
Liang Zhang ◽  
Li Yang ◽  
Zi-Wei Xia ◽  
Shi-Chang Yang ◽  
Wen-Hui Li ◽  
...  

2020 ◽  
Vol 39 (3) ◽  
pp. 783-803 ◽  
Author(s):  
Allison A. Fitzgerald ◽  
Louis M. Weiner

2019 ◽  
Vol 317 (2) ◽  
pp. L271-L282 ◽  
Author(s):  
Toru Kimura ◽  
James Monslow ◽  
Astero Klampatsa ◽  
Michael Leibowitz ◽  
Jing Sun ◽  
...  

Fibroblast activation protein (FAP), a cell surface serine protease, is upregulated on a subset of activated fibroblasts (often distinct from α-smooth muscle actin-expressing myofibroblasts) associated with matrix remodeling, including fibroblasts in idiopathic pulmonary fibrosis (Acharya PS, Zukas A, Chandan V, Katzenstein AL, Puré E. Hum Pathol 37: 352–360, 2006.). As FAP+fibroblasts could be pivotal in either breakdown and/or production of collagen and other matrix components, the goal of this study was to define the role of FAP+cells in pulmonary fibrosis in two established, but different, mouse models of chronic lung fibrosis: repetitive doses of intratracheal bleomycin and a single dose of an adenoviral vector encoding constitutively active TGF-β1 (Ad-TGFβ). To determine their role in fibrotic remodeling, FAP-expressing cells were depleted by injection of T cells expressing a chimeric antigen receptor specific for murine FAP in mice with established fibrosis. The contribution of FAP to the function of FAP-expressing cells was assessed in FAP knockout mice. Using histological analyses, quantification of soluble collagen content, and flow cytometry, we found that loss of FAP+cells exacerbated fibrosis in the bleomycin model, a phenotype largely recapitulated by the genetic deletion of FAP, indicating that FAP plays a role in this model. In contrast, depletion of FAP+cells or genetic deletion of FAP had little effect in the Ad-TGFβ model highlighting the potential for distinct mechanisms driving fibrosis depending on the initiating insult. The role of FAP in human lung fibrosis will need to be well understood to guide the use of FAP-targeted therapeutics that are being developed.


2020 ◽  
Vol 45 (2) ◽  
pp. 641-651
Author(s):  
Shuchong Mei ◽  
Yuan Zhang ◽  
Li Yu ◽  
Guoan Chen ◽  
Fuming Zi

Author(s):  
Mohammad Javad Mousavi ◽  
Elham Farhadi ◽  
Mohammad Vodjgani ◽  
Jafar Karami ◽  
Mohammad Naghi Tahmasebi ◽  
...  

Fibroblast-like synoviocytes (FLSs) have been introduced in recent years as a key player in the pathogenesis of rheumatoid arthritis (RA), but the exact mechanisms of their transformation and intracellular pathways have not yet been determined. This study aimed to investigate the role of fibroblast activation protein-alpha (FAP-α) in the regulation of genes involved in the transformation and pathogenic activity of RA FLSs. Synovial FLSs were isolated from RA patients and non-arthritic individuals (n=10 in both groups) and characterized; using immunocytochemistry and flow cytometry analysis. FLSs were divided into un-treated and Talabostat-treated groups to evaluate the FAP-α effect on the selected genes involved in cell cycle regulation (p21, p53, CCND1), apoptosis (Bcl-2, PUMA), and inflammatory and destructive behavior of FLSs (IL-6, TGF-β1, MMP-2, MMP-9, P2RX7). Gene expression analysis was performed by quantitative real-time polymerase chain reaction (qRTPCR), and immunoblotting was carried out to evaluate FAP-α protein levels. The basal level of FAP-α protein in RA patients was significantly higher than non-arthritic control individuals. However, no differences were observed between RA and non-arthritic FLSs, at the baseline mRNA levels of all the genes. Talabostat treatment significantly reduced FAPα protein levels in both RA and non-arthritic FLSs, however, had no effect on mRNA expressions except an upregulated TGF-β1 expression in non-arthritic FLSs. A significantly higher protein level of FAP-α in FLSs of RA patients compared with that of healthy individuals may point to the pathogenic role of this protein in RA FLSs. However, more investigations are necessary to address the mechanisms mediating the FAP-α pathogenic role in RA FLSs.


Sign in / Sign up

Export Citation Format

Share Document